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Quantitative Predictability of Carcinogenicity
of the Covalent Binding Index of Chemicals to
DNA: Comparison of the In Wvo and In Vitro
Assays
by Maurizio Taningher,* Giovanna Saccomanno,* Leonardo
Santi,* Sandro Grilli,t and Silvio Parodi*
The capability of covalent binding to DNA to predict the initiating potential of chemical carcin-
ogens was compared for the assays performed in vivo (rodent liver DNA) and in vitro (purified
DNA incubated in the presence of mouse and rat liver microsomes). A quantitative correlation
between DNA adducts and carcinogenic potency was investigated. The in vivo assay appeared
slightly, but not significantly, more predictive than the in vitro assay. Also predictivity was
slightly higher both in vivo and in vitro when we referred to liver carcinogenicity instead of
overall carcinogenicity. The predictive ability found for DNA covalent binding (both in vivo and in
vitro) was similar to that of many short-term tests (such as mutagenicity, DNA damage/repair,
SCEs, and cell transformation tests).
The covalent DNA binding, measured after incubation with DNA in vitro in the presence of liver
microsomes, could therfore be a reasonable short-term test offering greater rapidity of execution
and requiring the sacrifice of fewer animals than the corresponding in vivo test.
Introduction
From our knowledge of the carcinogenicity process,
genotoxicity seems to be especially related to initia-
tion. Possibly, other irreversible genomic alterations
occurring during progression can also be related to
genotoxic effects. Considering that genotoxicity is
related only to one or a few steps of the carcinogenic-
ity process, it is not surprising that the correlation
between carcinogenicity and genotoxicity is far from
perfect.
In addition, when a genotoxicity test is performed,
very often important discrepancies are found between
the metabolism in the test system and real metabo-
lism in the target cells for the initiation process. Even
the end points of genotoxicity tests are not necessa-
rily coincident with events relevant to the initiation
process.
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This relatively weak and partial correlation
between the carcinogenic process and genotoxic
events is reflected by the results of several studies
investigating correlations between carcinogenicity
and short-term tests (1-5).
In the papers published around 1975 and 1976, that
examined very strong genotoxic agents and very
clear-cut nongenotoxic compounds, a qualitative cor-
relation around 90% was observed between short-
term test results and carcinogenicity (1-3). In subse-
quent papers the average level of correlation was
around 70 to 80%. A global picture of the situation is
offered from a study performed in 1984 by the Inter-
national Commission for the Protection Against
Environmental Mutagens and Carcinogens (ICPEMC)
comparing carcinogenicity and genotoxicity in several
short-term tests. In Table 2 of that study, the mean of
the accuracy values (correct matchings) for 31 differ-
ent tests was around 78% (4). In a more recent assess-
ment by Tennant et al. (5), the level of qualitative
correlation (accuracy) was only about 60% for four
different in vitro short-terms tests. In the data base
used for this assessment, the number of compounds
suspected of being nongenotoxic carcinogens and/or
promoting agents was particularly significant. Other
authors (6-8) have expressed the opinion that whenTANINGHER ETAL.
the fraction of nongenotoxic chemicals goes up in a
data base the correlation between carcinogenicity and
short-term tests goes down.
Studies of correlation between carcinogenic potency
and quantitative degrees of response for positive
short-term test data have given similar results (9-14).
Again, a correlation is present, but relatively weak.
For a summary of the quantitative correlation stud-
ies, see Table 2 in our previous paper (15). In that
paper we also discussed the mathematical relation-
ship between qualitative and quantitative correlation
studies (15). The fact that a quantitative correlation
is always present, even if weak, suggests that the
additive role ofpromotion can attenuate, but not com-
pletely eliminate, the quantitative relationship
existing between initiating potency and carcinogenic
potency, provided that the bulk of the data base ana-
lyzed is not made up of pure, nongenotoxic chemicals.
As suggested above, differences between metabo-
lism in the activation system of the short-term test
and metabolism in the target cells for the initiation
process could be a second major cause of the weak
predictablilty of a given short-term test.
In the present study we tried to assess the rele-
vance of metabolic activation in vivo in liver cells,
versus an in vitro system of microsomes, again
obtained from liver cells. The amount of DNA adducts
was the common end point for both the in vivo and
the in vitro assays considered, so the reason for a
possible different degree of predictivity of the two
tests had to be essentially related to the different
metabolic activation. In addition, two other impor-
tant factors could decrease the relationship between
the in vivo and in vitro assays: first, DNA repair in
the whole liver system may modulate the final DNA
binding measured; second, there may be a difference
in reactivity between chromosomal DNA and the
purified DNA employed in the in vitro assay.
We had reason to suspect that a difference could
indeed exist, considering the results obtained in sev-
eral studies which we report below.
For instance, we compared the results obtained by
Mirsalis and Butterworth (16), who examined the
autoradiographic repair induced by dimethylni-
trosamine (DMN) in rat liver cells after treatment in
vivo and also the results obtained by Williams and
Laspia (17), who examined the autoradiographic
repair induced by DMN in primary cultures of
hepatocytes where DMN was already clearly active in
vivo at i0' mole/kg, but active in vitro only at 102 M
concentration.
In a paper by Kerklaan et al. (18), the induction of
repairable DNA damage in E. coli cells evaluated in a
host-mediated assay and in an in vitro assay were
compared. The effects of DMN and 1,2-dimethyl-
hydrazine (1,2-DMH) in E. coli cells recovered from
the liver of injected mice were already clearly detect-
able at the dosage of 50 gmole/kg. In the in vitro
assay (with the presence of mouse liver microsomes),
DMN showed an extremely weak (not dose-depen-
dent) response in a range of concentrations between
102 and 10' M; 1,2-DMH was completely inactive in
the in vitro assay up to a concentration of 50 mM.
In our comparison between adduct formation in vivo
and in vitro, the data available were mostly positive.
Because the qualitative approach requires a balanced
presence of positive and negative results, we were
forced to choose a quantitative approach in our corre-
lation study. We already used this methodolgy in sev-
eral investigations (9-13). On the other hand, as a ref-
erence point, we had a paper by Lutz presenting a
detailed quantitative study of the correlation between
carcinogenicity and DNA adduct formation in vivo (14).
Methods
The criteria adopted for the selection and computa-
tion of the data and for their correlation studies are
discussed in the following section.
Carcinogenic Potency
The carcinogenic potency data were mainly
obtained from the data base of Gold et al. (19). We
can expect a homogenous computation of potencies
for all the chemicals listed in it. In this data base the
carcinogenic potency is evaluated as TD50 and is
defined as "that chronic dose rate (in mg/kg body
weight/day), which would halve the actuarially
adjusted percentage of tumor-free animals at the end
of a standard experiment time-the standard lifespan
for the species" (20). For our computations, the TD,%
values were normalized in terms of gmole adminis-
tered per kilogram body weight. For a minor group of
chemicals, the above-mentioned data base was inte-
grated with our own data (21). Our computations
were brought in line with those of Gold et al. (19).
For each of the papers listed in the data base, we
used the lowest reported TD,% value (maximal onco-
genic potency) where carcinogenicity was considered
statistically significant (p < 0.05). When more than
one paper was reported in the data base for the same
chemical, one TD,% value was selected from each of the
papers. We then calculated the average of log TD,%.
Values of TD,% for liver tumors were also consid-
ered for correlation studies. The liver was the organ
where DNA adducts were measured.
Data were collected only from experiments on mice
and rats after oral or parenteral administration. Only
positive data were considered.
For our purposes, all the chemicals studied for the
correlation between in vitro and in vivo DNA cova-
lent binding and oncogenic potency had to be
genotoxic. We defined as genotoxic the chemicals
reported as positive in at least one-third of the
genotoxicity tests considered in the data base of
PaPajda and Rosenkranz (22). This partial arbitrary
cut-off point was established in order to exclude a
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study that could be suspected as promoting carcino-
gens more so than initiating carcinogens. One such
example could be diethylstilbestrol. We are aware
that this cut-off is an arbitrary one. However, it is
well known that genotoxic chemicals are not positive
in 100% of the tests. For instance, Ashby et al. esti-
mated that nongenotoxic chemicals could be positive
in about 20% of the tests, and very genotoxic chemi-
cals could be positive in about 80% of the tests (23).
Less potent genotoxic agents could give a response
between 80 and 20%. The level selected was one con-
sidered capable of excluding a significant fraction of
nongenotoxic chemicals without being too strict about
the genotoxic efficiency required. We were not able to
find a more objective threshold. On the other hand,
too much time and detailed data was required to ana-
lyze the quality of each manuscript and, if necessary,
to disagree with the results of the authors about the
initiating potential of the chemicals considered.
In Vivo DNA Covalent Binding
(In Vivo-CBD)
The data concerning the in vivo production of DNA
adducts were obtained mostly from papers by Lutz
(14, 24); some other data were obtained from the
papers used for computing the in vitro DNA covalent
binding index. According to Lutz (24), the in vivo-CBI
was defined as:
micromole chemical bound per mole nucleotides
millimole chemical administered per kilogram animal
The in vivo-CBI was computed for experiments on
animals sacrificed 4 to 24 hr after treatment. This
length of time is probably sufficient, usually being
much longer than the biological half-life in vivo of
most of the chemicals tested. In addition, the tempo-
ral range spanned by the different experiments can
be considered sufficiently narrow with regard to the
scale of CBI potencies. For this reason we did not
deem it necessary to modify the in vivo-CBI formula
proposed by Lutz (24).
The in vivo-CBI values concerned experiments on
mice and rats treated by oral or parenteral routes.
Only data on liver DNA adducts were collected. Only
data concerning positive results were considered.
When numerous data were available for the same
chemical, only the first ten values were considered.
In Vitro DNA Covalent Binding
(In Vitro-CBI)
The (in vitro-CBI) was defined as:
micromole chemical bound per mole nucleotides
(millimolar chemical in incubation mixture)*(incubation
time in minutes)
The in vitro-CBI values were computed from papers
cited in the ICRDB Cancergrams (25); data were
obtained also from Medline, Toxline, and Cancerline
(National Library of Medicine, Bethesda, MD, USA;
and Deutsches Institut fur Medizinische Dokumenta-
tion und Information (DIMDI), Cologne, FRG). When
numerous data for the same chemical were available
from different papers, only the first ten were used.
From a mathematical point of view, it is extremely
unlikely that the average of a random sample of 10
values should be totally unrelated to the entire popula-
tion of all available data. As a consequence, we consid-
ered a sample size of 10 data to be adequate. The in
vitro-CBI values were computed only from experi-
ments in which the metabolic activation was obtained
with microsomes prepared from the livers of mice or
rats. Different activation systems were not considered.
Data for seven directly alkylating chemicals (incuba-
tions without microsomes) were also used. The consid-
ered experiments used native double-stranded calf
thymus or salmon sperm DNA in the incubation mix-
tures. The molecular weight of the nucleotides was
assumed to be equal to 309. In the same paper when
more than one in vitro-CBI value was computable for
the same chemical, only the highest CBI value was
used. Only data concerning positive results were con-
sidered. Table 1 lists the chemicals for which we com-
puted at least one in vitro-CBI value.
Table 1. List of the carcinogens for which an in vitro-CBI was computable.'
Liver microsomes
Animal Enzymatic Loglo (in vitro-CBI)
. I . I . . .4 i - rs In vitro-CBI speciesb inductio
Aflatoxin B1
1140 R PB
2575 R WI
162 R PB
490 R PB
843 R PB
1010 R PB
2960 R
175 R
403 R MC
Aflatoxin GI
41.9 R PB
3-Amino-1-methyl-5H-pyrido (4,3-b)-indole; (Trp-P-2)
7.33 R MC
6.13 R PCB
)nc Concentration' mean value References
2.85 1.0
e
83
1.0
1.0
1.1
e
f
g
83
1.0
1.62
0.826
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(28)
(35)
(36)
(Continued on next page)
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Table 1. (Continued)
Liver microsomes
Animal Enzymatic Log,, (in vitro-CBI)
In vitro-CBI speciesb inductionc
Benz(a)anthracene
0.605 R MC
Benzene
1.99 M PB
Benzo(a)pyrene
194 R MC
20.1 R BF
3.34 R
49.2 R MC
23.2 R MC
1710 R MC
40.0 R MC
0.258 R MC
3.17 M WI
62.6 R MC
Bromoacetaldehyde
181 M
Bromobenzene
5.36 M PB
Bromoethanol
15.4 M
Carbon tetrachloride
0.110 M MC
Chlorobenzene
2.84 R PB
Cyclophosphamide
1.22 R PB
Dibenz(a,h)anthracene
0.192 R MC
1,2-Dibromo-3-chloropropane
1.03 R
1,2-Dibromoethane
6.63 M PB
18.7 M PB
8.02 M
3.30 M
0.263 R
3,3'-Dichlorobenzidine
1.87 R
1,1-Dichloroethane
1.20 M PB
1,2-Dichloroethane
8.74 R PB
8.17 M PB
0.827 M
Diethylnitrosamine
0.552 R PB
Diethylstilbestrol
1.33 R MC
15,16-Dihydro-11-methylcyclopenta(a)phenanthren-17-one
24.1 R
7,12-Dimethylbenz(a)anthracene
20.8 R PCB
3.41 R PB
3.22 R MC
6.01 R MC
2.60 R PCB
Dimethylnitrosamine
11.8 R WI
6.39 M A
3.17 R
Epichlorohydrin
0.155 R PB
Ethionine
0.162 R MC
a-Hexachlorocyclohexane
0.979 M PB
ly-Hexachlorocyclohexane
1.49 M PB
Hexachloroethane
6.31 M PB
Cnnrto \nme valu Reeene
Concentration' mean value References
0.22
0.67
-0.218
0.299
1.37
0.50
0.13
g
0.20
2.0
h
0.22
0.63
0.36
0.62
0.67
0.62
0.67
0.25
0.22
2.2
0.67
0.67
0.62
0.62
2.2
0.75
0.67
0.67
0.67
0.62
1.6
0.80
0.25
1.0
0.22
h
1.0
1.6
4.0
1.6
0.67
0.20
0.20
0.67
2.26
0.729
1.19
-0.959
0.453
0.0864
-0.717
0.0128
0.587
0.272
0.0792
0.591
-0.258
0.124
1.38
0.711
0.792
-0.810
-0.790
-0.00922
0.173
0.800
(37)
(38)
(39)
(40)
(41)
(34)
(42)
(43)
(44)
(37)
(45)
(31)
(46)
(47)
(46)
(48)
(49)
(50)
(37)
(51)
(52)
(53)
(46)
(54)
(51)
(55)
(56)
(52)
(53)
(54)
(57)
(58)
(59)
(60)
(61)
(37)
(44)
(62)
(63)
(64)
(56)
(65)
(66)
(67)
(67)
(68)
(Continued on next page)
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Table 1. (Continued)
Liver microsomes
Animal Enzymatic Log1l (in vitro-CBI)
In vitro-CBI speciesb induction" Concentration d mean value References
Isophosphamide
21.9 R PB k 1.34 (69)
7-Methylbenz(c)acridine
24.7 M MC 1.5 1.39 (70)
3-Methylcholanthrene
13.6 R MC h 1.78 (44)
266 R 2.7 (71)
Mycophenolic acid
1.11 R 1 0.0453 (72)
N-Nitrosopiperidine
0.169 R PB 1.6 -0.772 (57)
Pentachloroethane
12.9 M PB 0.67 1.11 p
Quinoline
4.00 R PCB 1.0 0.602 (73)
1,1,2,2-Tetrachloroethane
2.92 M PB 0.67 0.465 (74)
Tetrachloroethylene
3.74 R PB 0.67 0.573 (75)
1,1,1-Trichloroethane
0.675 M PB 0.67 -0.171 (76)
1,1,2-Trichloroethane
16.4 R PB 0.67 1.21 (77)
Trichloroethylene
0.316 M PB 0.58 -0.294 (78)
0.817 M PB 2.0 (79)
Diethylsulfate
0.347 -0.460 (80)
Dimethylsulfate
1.77 0.248 (81)
1,1'-Ethylene-bis-(1-nitrosourea)
2.06 0.314 (82)
Ethylmethane sulfonate
0.330 -0.601 (80)
0.238 (83)
0.200 (81)
Ethylnitrosourea
0.129 -0.321 (82)
0.552 (80)
1.53 (81)
Methylmethane sulfonate
2.57 0.420 (83)
2.69 (84)
Methylnitrosourea
4.12 0.758 (82)
2.50 (85)
18.3 (81)
Semicarbazide
0.00158 -2.80 (86)
'In vitro-CBI: in vitro DNA covalent binding index, as defined in "Methods."
bM, mouse; R, rat.
'A, acetone; BF, 5,6-benzoflavone; MC, 3-methylcholanthrene; PB, phenobarbital; PCB, polychlorinated biphenyls; WI, without induction.
dThe concentration is expressed in mg protein/mL incubation mixture, unless otherwise stated.
eo.50 nmole P-450/mL incubation mixture.
fo.25 nmole P-450/mL incubation mixture.
'-'Microsomes from: 0.25; 0.7; 0.3; 0.14; 0.25 and 2.0 g of liver incubated in: 5, 6, 6, 3, 3, and 50 mL of incubation mixture, respectively, for
footnotes g, h, i, j, k, L
'In the presence of cytosolic proteins.
'DNA source not specified.
°HeLa cell DNA.
POur unpublished data.
Quantitative Correlation Studies When more than one potency value was available for
In a previous paper we showed that general sets of the same compound, we used the average of log1o
values concerning oncogenic potencies or short-term potencies. Usually, the clouds of points in graphs of
test potencies tend to display approximately a log- log1o of potency X versus log1o of potency Y are also
normal distribution (15). As a consequence, the corre- compatible with a linear regression analysis and par-
lation studies were made between log1o of potencies. ametric statistics (data not reported).
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In order to determine the effects of a possible
deviation from a log-normal distribution, the differ-
ent correlations were also analyzed with the
nonparametric Spearman's rank correlation coeffi-
cient, as reported in Tables 2 and 3.
Results
As detailed in the "Methods" section, the main con-
ditions adopted for normalizing the data were studies
on mice and rats treated by oral or parenteral routes
for carcinogenicity data, on mouse and rat liver DNA
for in vivo-CBI data, and using mouse or rat liver-
metabolizing systems for in vitro-CBI data.
In these conditions, carcinogenicity data for 49
genotoxic chemicals (as defined in "Methods") and in
vivo-CBI data for 44 genotoxic chemicals were availa-
ble. They had in vitro-CBI values spanning a range
more than five logs1o wide, and totaled 48 compounds.
However, 19 of them (i.e., chemicals No. 7-11, 17, 20,
21, 26-28, 30, 32, 34, 35, 39, 41, 43, 48) could not be used
for any correlation because in vivo data were either
unavailable or the chemicals were not defined as
genotoxic compounds. Thus, we were left with 29 use-
ful compounds. In Table 1 both the in vitro-CBI val-
ues for each experiment and average log1o (in
vitro-CBI) values were reported; however, for correla-
tion studies only the average log1o values were used.
We wanted to consider only genotoxic compounds.
The importance of this point may be illustrated by
considering that during their lifetime animals sub-
jected to chronic carcinogenicity experiments with
promoters can be exposed to a background level of
initiating events that are sufficient to combine with
the effects of a full-promoting treatment, thus gener-
ating a detectable tumor incidence. As a consequence,
even purely or prevalently promoting agents can give
positive results in chronic carcinogenicity experi-
ments in rodents. However, a study of the correlation
between DNA adduct formation and carcinogenicity
makes sense only if we deal with initiating agents.
In order to increase the probability that we were
dealing with an initiator and not a promoter, we
established the condition that a chemical could be
used in our correlation study only if it was positive in
at least one out of three genotoxicity tests, as judged
Table 2. Quantitative correlations among overall carcinogenicity (TD50), in vivo DNA covalent binding (in vivo-CBI),
and in vitro DNA covalent binding (in vitro-CBI).'
Correlation
No. of Correlation coefficient
Couple of parameters chemicals coefficient, rb per ranks, r,d
Overall correlation
Log (in vitro-CBI) = f (-Log [TD50]) 26 0.44 0.30
Log (in vivo-CBI) = f (-Log[TDs,]) 41 0.52 0.51
Log (in vitro-CBI) f (Log [in vivo-CBI]) 21 0.64 0.53
Correlation for the same 18 chemicals
Log (in vitro-CBI) = f (-Log [TD50]) 18 0.42c 0.27
Log (in vivo-CBI) = f (-Log [TD50]) 18 0.46c 0.36
Log (in vitro-CBI) = f (Log [in vivo-CBI]) 18 0.58 0.47
aThe definitions of the parameters are reported in "Methods." In vitro-CBI data were obtained from the data base listed in Table 1.
In vivo-CBI data were obtained from (14,24,28,33,41,50,53,65,66,68,74-76); our unpublished data were used for pentachloroethane. TD50
were obtained from Gold et al. and Parodi et al. (19,21).
bParametric statistical computations according to Snedecor and Cohran (87). The r values are statistically different from zero with
a p <0.05 except where otherwise specified.
Cr values for which p < 0.10.
dNonparametric statistical computations according to Siegel (88).r, = nonparametric correlation coefficient according to Spearman.
Table 3. Quantitative correlations among liver carcinogenicity (TD50), in vivo DNA covalent binding (in vivo-CBI), and
in vitro DNA covalent binding (in vitro-CBI)-.
Correlation
No. of Correlation coefficient
Couple of parameters chemicals coefficient, rb per ranks, r,d
Overall correlation
Log (in vitro-CBI) = f (-Log [TD50]) 13 0.64 0.55
Log (in vivo-CBI) = f (-Log[TD50]) 25 0.57 0.63
Correlation for the same nine chemicals
Log (in vitro-CBI) = f (-Log [TD50]) 9 0.66c 0.50
Log (in vivo-CBI) = f (-Log [TD50]) 9 0.75 0.85
aThe definitions of the parameters are reported in "Methods." In vitro-CBI data were obtained from the data base listed in Table 1.
In vivo-CBI data were obtained from (14,24,28,33,41,50,53,65,66,68,74-76); our unpublished data were used for pentachloroethane. TD50
were obtained from Gold et al. and Parodi et al. (19,21).
bParametric statistical computations according to Snedecor and Cohran (87). The r values are statistically different from zero with
a p <0.05 except where otherwise specified.
Cr values for which p <0.10.
dNonparametric statistical computations according to Siegel (88).r, = nonparametric correlation coefficient according to Spearman.
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FIGURE 1. Distribution of the log10 (in vitro-CBI) mean values
referred to the 48 different chemicals listed in Table 1.
from the data base of Rosenkranz and Palajda (22).
We analyzed the distribution of the mean values of
log1o (in vitro-CBI) concerning the 48 chemicals listed
in Table 1. As shown by the histogram in Figure 1,
these resulting values were approximately log-nor-
mally distributed, in accordance with our previous
observations (15). As a consequence of this result, we
considered it acceptable to apply parametric statistics
to log1o of potencies.
Table 1 also details the data base of the in vitro-CBI
values we computed, and gives an idea of the differ-
ences in experimental conditions present in the in vitro
experiments. Although we normalized the results for
drug concentration and incubation time, from the
point of view of metabolic activation, the experimental
conditions were definitely less homogenous than those
for the in vivo experiments. However, as the reader
will see in the following analysis, the additional statis-
tical noise brought about by this lack of data homoge-
neity apparently did not play an important role. As
can be seen in Table 1, for 57 out of the 87 experiments
listed, it was possible to normalize the data for
microsomal protein concentration. By calculating the
correlation between normalized and nonnormalized
data, we found r = 0.87, suggesting that the lack of this
normalization is not terribly disruptive. On the other
hand, by using only normalized data, we would have
impoverished our data set too much.
With the data we collected, it was possible to study
the quantative correlation with carcinogenicity of the
in vitro-CBI for an overall group of 26 genotoxic
chemicals, and the in vivo-CBI for an overall group of
41. A correlation study with more homogeneous data
was possible with 18 chemicals where triplets of data
on carcinogenicity, in vivo and in vitro-CBI, were
available. The results are reported in Table 2.
No statistically significant differences were
observed in predictivity of carcinogenicity after dis-
carding from the correlation four directly alkylating
chemicals (i.e., chemicals No. 44-47 of Table 1), whose
data were available both for in vitro-CBI and in
vivo-CBI.
As previously reported, quantitative correlation
levels with carcinogenicity around 0.4-0.5 are very
common in most of the short-term tests (15). In this
respect the results reported in Table 2 seem to sug-
gest that DNA adduct formation can contribute to
our knowledge of genotoxicity and the initiating
potential of a given chemical with a degree of efficacy
similar to that of the most common short-term tests.
This conviction is reinforced by the fact that the dif-
ferences in quantitative predictivity previously found
for different short-term tests never reach a level of
clear statistical significance (15).
In a recent paper, Lutz reported a correlation level
with carcinogenicity of the in vivo-CBI with r = 0.81
(14). Compared with our r = 0.52, this difference is
statistically significant (p=0.03). However, it has to
be remembered that we considered 12 more chemicals
in addition to the 29 considered by Lutz, and we also
considered additional experiments for those same 29
chemicals. Moreover, Lutz considered only carcinoge-
nicity results obtained in the same species used for
DNA adducts.
The results obtained with the Spearman's test were
not very different from those obtained with the para-
metric approach. The small difference observed is
probably related more to the small size of the set
considered than to an important systematic deviation
from normality of the log of potencies of the general
population of data.
As reported in Table 2, we have also investigated
the quantitative correlation existing between in
vitro-CBI and in vivo-CBI data. The correlation coef-
ficient with r value around 0.6 found in this study
appears relatively high if compared with r values
around 0.4, previously found when comparing differ-
ent short-term tests with one another (9,10). This
finding confirms that the highest correlation is
reached with tests that use the same biological
endpoint. As an example, in a previous study, the in
vivo alkaline DNA elution test, which looks at the
endpoint DNA damage, appeared to be correlated
with the in vivo-CBI by r = 0.66. By contrast, it was
correlated by lower r values around 0.3, with tests
that use different endpoints such as Ames' test and in
vitro cell transformation test (9).
In Table 3 we reported the correlation between
DNA adducts and carcinogenicity in the liver. In this
case the sample size becomes further reduced. The
differences between r values obtained for overall
tumors and the r values obtained for liver tumors are
not statistically significant. However, a general trend
seems to emerge suggesting that the identity of the
target organ perhaps plays some role in determining
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the correlation level. Even in this case, the predictivi-
ties of in vitro-CBI and in vivo-CBI are very similar.
Discussion
In vivo DNA binding has already been proposed by
Lutz (14, 24) as a valid short-term test for assessing
genotoxicity.
To our knowledge, this is the first time that in vivo
and in vitro covalent bindings have been compared in
terms of their predictivity of carcinogenicity. In vitro
tests are usually less expensive and more rapid than
in vivo tests. In addition, the use of in vitro tests can
significantly reduce the number of animals used to
assess the initiating potential of a given chemical as a
carcinogen. On the other hand, the general knowledge
that we have about absorption, metabolism, and cat-
abolism of chemicals leads us to suspect that in vivo
assays could be more predictive than assays in vitro.
As a matter of fact, the papers mentioned in the
"Introduction" (16-18) seem to suggest that for DMN
and 1,2-DMH, two important classical initiating car-
cinogens, the in vivo assay is indeed much better than
the in vitro assay.
However, this difference is no longer evident when
we look at the globality of the 30 to 40 chemicals that
we have examined in this work. Admittedly, the sen-
sitivity of the experimental approach adopted for
comparing in vitro and in vivo predictivity is not very
great (a larger data base was not available); hence, it
remains possible that the in vivo assay is slightly
more predictive than the in vitro assay, as suggested
by the small differences in correlation coefficents
found in our results. We have to stress that only lim-
ited conclusions can be justified by a data base of the
size mentioned above.
In a recent study Tennant et al. (5) found the quali-
tative correlation between the carcinogenicity in mice
and rats to be only 67%. Given that even the level of
this type of internal correlation is limited, we cannot
expect especially high correlation levels between
short-term tests and carcinogenicity. In this perspec-
tive the levels of predictivity found in our study can
be considered to be reasonably good.
If we compare the in vitro-CBI evaluation (in the
presence of liver microsome activation) with other
tests, the quantitative predictivity of this assay seems
to be similar to that of other classical short-term
tests, such as Ames' test, SCEs in mouse bone mar-
row, morphological transformation in vitro, DNA
fragmentation in vivo (liver), and DNA repair in
vitro (hepatocytes) (15).
In conclusion, in vitro-CBI seems to have a predic-
tivity similar to most short-term tests and is not
clearly inferior to in vivo-CBI. We think that in
vitro-CBI can be proposed as another short-term test
in its own right, especially in the perspective of reduc-
ing the number of animals used in toxicity studies.
Our data could also suggest that for other types of
short-term tests (mutagenicity and chromosomal
damage), in vivo versions of the tests are not necessa-
rily dramatically more predictive than the corre-
sponding version in vitro (with liver microsome
activation). This could be a subject which deserves
further investigation.
Finally, it could be interesting to compare in vitro
and in vivo-CBI for a homogeneous class of chemi-
cals. In this respect we have started investigation
with the family of chloroethanes.
This work was supported by an ECC contribution (grant EV 4V-
0036-I); by grants from CNR Progetto Finalizzato "Oncologia" con-
tracts 87.01566.44 and 87.01315.44; from Ministero della Pubblica
Istruzione, Rome; Associazione Italiana per la Ricera sul Cancro,
Milan; and Regione Liguria, Genoa, Italy.
We wish to thank Gabriella Frigerio for her careful typing of
the manuscript.
REFERENCES
1. McCann, J., Choi, E., Yamasaki, E., and Ames, B. N. Detection
of carcinogens as mutagens in the Salmonella/microsome test:
assay of 300 chemicals. Proc. Natl. Acad. Sci. (U.S.) 72:
5135-5139 (1975).
2. McCann, J., and Ames, B. N. Detection of carcinogens as
mutagens in the Salmonella/microsome test: assay of 300
chemicals: discussion. Proc. Natl. Acad. Sci. (U.S.) 73: 950-954
(1976).
3. Sugimura, T., Yahagi, T., Nagao, M., Takeuchi, M., Kawachi,
T., Hara, K., Yamasaki, E., Matsushima, T., Hashimoto, Y.,
and Okada, M. Validity of mutagenicity tests using microbes
as a rapid screening method for environmental carcinogens.
In: Screening Tests in Chemical Carcinogenesis, Vol. 12 (R.
Montesano, H. Bartsch, and L. Tomatis, Eds.), International
Agency for Research on Cancer, Lyon, 1976, pp. 81-101.
4. International Commission for Protection Against Environ-
mental Mutagens and Carcinogens. ICPEMC Publication No 9.
Report of ICPEMC Task Group 5 on the differentiation
between genotoxic and non-genotoxic carcinogens. Mutat. Res.
133: 1-49 (1984).
5. Tennant, R. W., Margolin, B. H., Shelby, M. D., Zeiger, E.,
Haseman, J. K., Spalding, J., Caspary, W., Resnik, M.,
Stasiewicz, S., Anderson, B., and Minor, R. Prediction of chem-
ical carcinogenicity in rodents from in vitro genetic toxicity
assays. Science 236: 933-941 (1987).
6. Rosenkranz, H. S. Foreword (Special Issue: Strategies for the
deployment ofbatteries ofshort-term tests). Mutat. Res. 205: 1
(1988).
7. International Commission for Protection Against Environ-
mental Mutagens and Carcinogens. ICPEMC Publication No.
16. Testing for mutagens and carcinogens; the role of
short-term genotoxicity assays. Mutat. Res. 205: 3-12 (1988).
8. Ramel, C. Short-term testing-are we looking at the wrong
endpoints? Mutat. Res. 205: 13-24 (1988).
9. Parodi, S., Taningher, M., and Santi, L. Alkaline elution in
vivo: fluorimetric analysis in rats. Quantitative predictivity of
carcinogenicity, as compared with other short-term tests. In:
Indicators of Genotoxic Exposure: Banbury Report No. 13 (B.
A. Bridges, B. E. Butterworth, and I. B. Weinstein, Eds.), Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982, pp.
137-155.
10. Parodi, S., Taningher, M., Russo, P., Pala, M., Vecchio, D.,
Fassina, G., and Santi, L. Quantitative predictivity of the
transformation in vitro assay compared with the Ames test. J.
Toxicol. Environ. Health 12: 483-510 (1983).
11. Parodi, S., Taningher, M., and Santi, L. Induction of prene-
oplastic nodules: Quantitative predictivity of carcinogenicity.
Anticancer Res. 3: 393-400 (1983).
12. Parodi, S., Taningher, M., Zunino, A., Ottaggio, L., De Ferrari,
M., and Santi, L. Quantitative predictivity of carcinogenicityIN VIVO AND IN VITRO COVALENT BINDING 191
for sister chromatid exchanges in vivo. In: Sister Chromatid
Exchange: 25 Years of Experimental Research, Part A (R. R.
Tice, and A. Hollaender, Eds.), Plenum Press, New York, 1984,
pp. 409-429.
13. Bolognesi, C., Taningher, M., Parodi, S., and Santi, L. Quanti-
tative predictivity of carcinogenicity of the autoradiographic
repair test (primary hepatocyte cultures) for a group of 80
chemicals belonging to different chemical classes. Environ.
Health Perspect. 70: 247-253 (1986).
14. Lutz, W. K. Quantitative evaluation of DNA binding data for
risk estimation and for classification of direct and indirect
carcinogens. J. Cancer Res. Clin. Oncol. 112: 85-91 (1986).
15. Parodi, S., Taningher, M., and Santi, L. Utilization of the
quantitative component of positive and negative results of
short-term tests. Mutat. Res. 205: 283-294 (1988).
16. Mirsalis, J. C., and Butterworth, B. E. Detection of unscheduled
DNA synthesis in hepatocytes isolated from rats treated with
genotoxic agents: an in vivo-in vitro assay for potential carcino-
gens and mutagens. Carcinogenesis 1: 621-25 (1980).
17. Williams, G. M., and Laspia, M. F. The detection of various
nitrosamines in the hepatocyte primary culture/DNA repair
test. Cancer Lett. 6: 199-206 (1979).
18. Kerklaan, P. R. M., Bouter, S., Van Elburg, P. A., and Mohn, G.
R. Evaluation of the DNA-repair host-mediated assay. I.
Induction of repairable DNA damage in E. coli cells recovered
from liver, spleen, lungs, kidneys, and the bloodstream of mice
treated with methylating carcinogens. Mutat. Res. 148: 1-12
(1985).
19. Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de
Veciana, M., Levinson, R., Hooper, N. K., Havender W. R.,
Bernstein, L., Peto, R., Pike, M. C., and Ames, B. N. A carcino-
genic potency database of the standardized results of animal
bioassays. Environ. Health Perspect. 58: 9-319 (1984).
20. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N.
The TD50: a proposed general convention for the numerical
description of the carcinogenic potency of chemicals in
chronic-exposure animal experiments. Environ. Health Per-
spect. 58: 1-8 (1984).
21. Parodi, S., Taningher, M., Ugolini, D., and Santi, L., (Eds.), A
database of carcinogenic potencies (problems related to the
use ofthe quantitative component of the information). Istituto
Nazionale per la Ricerca sul Cancro, Genva, 1988, p. 279.
22. Palajda, M., and Rosenkranz, H. S. Assembly and preliminary
analysis of a genotoxicity data base for predicting carcino-
gens. Mutat. Res. 153: 79-134 (1985).
23. Ashby, J., de Serres, F. J., Draper, M., Ishidate, M., Jr., Margo-
lin, B. H., Matter, B., and Shelby, M. D. Overview and conclu-
sion ofthe IPCS collaborative study on in vitro assay systems.
Progr. Mutat. Res. 5: 117-174 (1985).
24. Lutz, W. K. In vivo covalent binding of organic chemicals to
DNA as a quantitative indicator in the process of chemical
carcinogenesis. Mutat. Res. 65: 289-356 (1979).
25. International Cancer Research Data Bank Cancergram Series,
CK 11, U.S. Dept. of Health and Human Services Ed.
(1979-1985).
26. Guengerich, F. P. Similarity of nuclear and microsomal cyto-
chromes P-450 in the in vitro activation of aflatoxin B,.
Biochem. Pharmacol. 28: 2883-2890 (1979).
27. Lotlikar, P. D., Insetta, S. M., and Jhee, E. C. Cytosolic inhibi-
tion of liver microsome-mediated binding of aflatoxin B,
(AFB1) to DNA. Proc. Am. Assoc. Cancer Res. 21: 78 (1980).
28. Garner, R. C., Martin, C. N., Smith, J. R. L., Coles, B. F., and
Tolson, M. R. Comparison of aflatoxin B, and aflatoxin G,
binding to cellular macromolecules in vitro, in vivo and after
peracid oxidation; characterization of the major nucleic acid
adducts. Chem.-Biol. Interact. 26: 57-73 (1979).
29. Bhattacharya, R. K., Firozi, P. F., and Aboobaker, V. S. Fac-
tors modulating the formation of DNA adduct by aflatoxin B,
in vitro. Carcinogenesis 5: 1359-1362 (1984).
30. Essigmann, J. M., Croy, R. G., Nadzan, A. M., Busby, W. F., Jr.,
Reinhold, V. N., Buchi, G., and Wogan, G. N. Structural identi-
fication of the major DNA adduct formed by aflatoxin B1 in
vitro. Proc. Natl. Acad. Sci. (U.S.) 74: 1870-1874 (1977).
31. Gurtoo, H. L., and Dave, C. V. In vitro metabolic conversion of
aflatoxins and benzo(a)pyrene to nucleic acid-binding metabo-
lites. Cancer Res. 35: 382-389 (1975).
32. Raj, H. G., Clearfield, M. S., and Lotlikar, P. D. Comparative
kinetic studies on aflatoxin Bl-DNA binding and aflatoxin
Bl-glutathione conjugation with rat and hamster livers in
vitro. Carcinogenesis 5: 879-884 (1984).
33. Lotlikar, P. D., Clearfield, M. S., and Jhee, E. C. Effect of
butylated hydroxyanisole on in vivo and in vitro hepatic
aflatoxin B,-DNA binding in rats. Cancer Lett. 24: 241-250
(1984).
34. Alexandrov, K., and Frayssinet, C. Microsome-dependent
binding of benzo(a)pyrene and aflatoxin B1 to DNA, and
benzo(a)pyrene binding to aflatoxin-conjugated DNA. Cancer
Res. 34: 3289-3295 (1974).
35. Nemoto, N., Kusumi, S., Takayama, S., Nagao, M., and
Sugimura, T. Metabolic activation of 3-amino-5H-pyrido
(4,3-b)indole, a highly mutagenic principle in tryptophan
pyrolysate, by rat liver enzymes. Chem.-Biol. Interact. 27:
191-198 (1979).
36. Hashimoto, Y., Takeda, K, Shudo, K., Okamoto, T., Sugimura,
T., and Kosuge, T. Rat liver microsome-mediated binding to
DNA of 3-amino-1-methyl-5H-pyrido(4,3-b) indole, a potent
mutagen isolated from tryptophan pyrolysate. Chem.-Biol.
Interact. 23: 137-140 (1978).
37. Prodi, G., Grilli, S., Mazzullo, M., Colacci, A., and Arfellini, G.
Comparison between photo-induction and microsomal activa-
tion of polycyclic hydrocarbons with different oncogenic
potency. Toxicol. Pathol. 12: 185-188 (1984).
38. Arfellini, G., Grilli, S., Colacci, A., Mazzullo, M., and Prodi, G.
In vivo and in vitro binding of benzene to nucleic acids and
proteins of various rat and mouse organs. Cancer Lett. 28:
159-168 (1985).
39. Ashurst, S. W., and Cohen, G. M. A benzo(a)pyrene-7,8-
dihydrodiol-9,10-epoxide is the major metabolite involved in
the binding of benzo(a)pyrene to DNA in isolated viable rat
hepatocytes. Chem.-Biol. Interact. 29: 117-127 (1980).
40. Lubet, R. A., Capdevila, J., and Prough, R. A. The metabolic
activation of benzo(a)pyrene and 9-hydroxybenzo(a)pyrene by
liver microsomal fractions. Int. J. Cancer 23: 353-357 (1979).
41. Jaggi, W., Lutz, W. K., and Schlatter, Ch. Comparative studies
on the covalent binding of the carcinogen benzo(a)pyrene to
DNA in various model systems. Experientia 35: 631-632 (1979).
42. Jernstrom, B., Vadi, H., and Orrenius, S. Formation in isolated
rat liver microsomes and nuclei of benzo(a)pyrene metabolites
that bind to DNA. Cancer Res. 36: 4107-4113 (1976).
43. Hesse, S., Jernstrom, B., Martinez, M., Moldeus, P., Chris-
todoulides, L., and Ketterer, B. Inactivation of DNA binding
metabolites of benzo(a)pyrene and benzo(a)pyrene-7,8-
dihydrodiol by glutathione and glutathione S-transferases.
Carcinogenesis 3: 757-760 (1982).
44. Grilli, S., Rocchi, P., and Prodi, G. Non-enzymatic and micro-
some-dependent binding of polycyclic hydrocarbons to DNA
and polynucleotides. Chem.-Biol. Interact. 11: 351-363 (1975).
45. Ioannou, Y. M., Wilson, A. G. E., and Anderson, M. W. Effect
of butylated hydroxyanisole on the metabolism of
benzo(a)pyrene and the binding of metabolites to DNA, in
vitro and in vivo, in the forestomach, lung, and liver of mice.
Carcinogenesis 3: 739-745 (1982).
46. Banerjee, S., Van Duuren, B. L., and Kline, S. A. Interaction of
potential metabolites of the carcinogen ethylene dibromide
with protein and DNA in vitro. Biochem. Biophys. Res. Com-
mun. 90: 1214-1220 (1979).
47. Colacci, A., Arfellini, G., Mazzullo, M., Prodi, G., and Grilli, S.
The covalent binding of bromobenzene with nucleic acids. Tox-
icol. Pathol. 13: 276-282 (1985).
48. Rocchi, P., Prodi, G., Grilli, S., and Ferreri, A. M. In vivo and
in vitro binding of carbon tetrachloride with nucleic acids and
proteins in rat and mouse liver. Int. J. Cancer 11: 419-425
(1973).
49. Grilli, S., Arfellini, G., Colacci, A., Mazzullo, M., and Prodi, G.
In vivo and in vitro covalent binding of chlorobenzene to
nucleic acids. Gann 76: 745-751 (1985).192 TANINGHER ETAL.
50. Hemminki, K. Binding of metabolites of cyclophosphamide to
DNA in a rat liver microsomal system and in vivo in mice.
Cancer Res. 45: 4237-4243 (1985).
51. Inskeep, P. B., and Guengerich, F. P. Glutathione-mediated
binding of dibromoalkanes to DNA: specificity of rat gluta-
thione-S-transferases and dibromoalkane structure. Carcino-
genesis 5: 805-808 (1984).
52. Colacci, A., Mazzullo, M., Arfellini, G., Prodi, G., and Grilli, S.
In vitro microsome and cytosol-mediated binding of
1,2-dichloroethane and 1,2-dibromoethane with DNA. Cell
Biol. Toxicol. 1: 45-55 (1985).
53. Arfellini, G., Bartoli, A., Colacci, S., Mazullo, M., Galli, M. C.,
Prodi, G., and Grilli, S. In vivo and in vitro binding of
1,2-dibromoethane and 1,2-dichloroethane to macromolecules
in rat and mouse organs. J. Cancer Res. Clin. Oncol. 108:
204-213 (1984).
54. Banerjee, S., and Van Duuren, B. L. Binding of carcinogenic
halogenated hydrocarbons to cell macromolecules. J. Natl.
Cancer Inst. 63: 707-711 (1979).
55. Bratcher, S. C., and Sikka, H. C. Binding of 3,
3'-dichlorobenzidine to DNA and polyribonucleotides in vitro.
Chem.-Biol. Interact. 38: 369-375 (1982).
56. Colacci, A., Arfellini, G., Mazzullo, M., Prodi, G., and Grilli, S.
Genotoxicity of 1,1-dichloroethane. Res. Commun. Chem.
Pathol. Pharmacol. 49: 243-255 (1985).
57. Lai, D. Y., Arcos, J. C., and Argus, M. F. Factors influencing
the microsome- and mitochondria-catalyzed in vitro binding
of diethylnitrosamine and N-nitrosopiperidine to deox-
yribonucleic acid. Biochem. Pharmacol. 28: 3545-3550 (1979).
58. Blackburn, G. M., Thompson, M. H., and King, H. W. S. Bind-
ing of diethylstilboestrol to deoxyribonucleic acid by rat liver
microsomal fractions in vitro and in mouse fetal cells in cul-
ture. Biochem. J. 158; 643-646 (1976).
59. Coombs, M. M., Bhatt, T. S., and Vose, C. W. The relationship
between metabolism, DNA binding, and carcinogenicity of
15,16-dihydro-11-methylcyclopenta(a)phenanthren-17-one in
the presence of a microsomal enzyme inhibitor. Cancer Res.
35: 305-309 (1975).
60. Bigger, C. A. H., Tomaszewski, J. E., Dipple, A., and Lake, R. S.
Limitations of metabolic activation systems used with in vitro
tests for carcinogens. Science 209: 503-505 (1980).
61. Chou, M. W., and Yang, S. K. Identification of four trans-
3,4-dihydrodiol metabolites of 7,12-dimethyl-
benz(a)anthracene and their in vitro DNA-binding activities
upon further metabolism. Proc. Natl. Acad. Sci. (U.S.) 75:
5466-5470 (1978).
62. Bigger, C. A. H., Tomaszewski, J. E., Andrews, A. W., and
Dipple, A. Evaluation of metabolic activation of
7,12-dimethylbenz(a)anthracene in vitro by Aroclor
1254-induced rat liver S-9 fraction. Cancer Res. 40: 655-661
(1980).
63. Lai, D. Y., Myers, S. C., Woo, Y.-T., Greene, E. J., Friedman, M.
A., Argus, M. F., and Arcos, J. C. Role of dimethylni-
trosamine-demethylase in the metabolic activation of
dimethylnitrosamine. Chem.-Biol. Interact. 28:107-126 (1979).
64. Sipes, I. G., Slocumb, M. L., and Holzman, G. Stimulation of
microsomal dimethylnitrosamine-N-demethylase by pre-
treatment of mice with acetone. Chem.-Biol. Interact. 21:
155-166 (1978).
65. Mazzullo, M., Colacci, A., Grilli, S., Prodi, G., and Arfellini, G.
In vivo and in vitro binding of epichlorohydrin to nucleic
acids. Cancer Lett. 23: 81-90 (1984).
66. Grilli, S., Ferreri, A. M., Rocchi, P., and Prodi, G. In vivo and
in vitro binding of ethionine with nucleic acids. Gann 65:
507-511 (1974).
67. Iverson, F., Ryan, J. J., Lizotte, R., and Hierlihy, S. L. In vivo
and in vitro binding of a- and -y-hexachlorocyclohexane to
mouse liver macromolecules. Toxicol. Lett. (Amst.) 20: 331-335
(1984).
68. Lattanzi, C., Colacci, A., Grilli, S., Mazzullo, M., Prodi, G.,
Taningher, M., and Turina, M. P. Binding of hexachloroethane
to biological macromolecules from rat and mouse organs. J.
Toxicol. Environ. Health 24: 403-411 (1988).
69. Allen, L. M., and Creaven, P. J. Effect of microsomal activa-
tion on interaction between isophosphamide and DNA. J.
Pharm. Sci. 61: 2009-2011 (1972).
70. Boux, L. J., and Holder, G. M. The activation of DNA binding
of 7-methylbenz(c)acridine catalysed by mouse liver micro-
somes. Cancer Lett. 25: 333-342 (1985).
71. Eastman, A., and Bresnick, E. Metabolism and DNA binding
of 3-methylcholanthrene. Cancer Res. 39: 4316-4321 (1979).
72. Nery, R., and Nice, E. The metabolism and binding of (14C)
mycophenolic acid in the rat. J. Pharm. Pharmac. 23: 842-847
(1971).
73. Tada, M., Takahashi, K., Kawazoe, Y., and Ito, N. Binding of
quinoline to nucleic acid in a subcellular microsomal system.
Chem.-Biol. Interact. 29: 257-266 (1980).
74. Colacci, A., Grilli, S., Lattanzi, C., Prodi, G., Turina, M. P., and
Mazzullo, M. The covalent binding of 1,1,2,2-tetrachloroethane
to macromolecules of rat and mouse organs. Mutagen. Carcin-
ogen. Teratogen. 7: 465-474 (1987).
75. Mazzullo, M., Grilli, S., Lattanzi, C., Prodi, G., Turina, M. P.,
and Colacci, A. Evidence of DNA binding activity of per-
chloroethylene. Res. Commun. Chem. Pathol. Pharmacol. 58:
215-235 (1987).
76. Turina, M. P., Colacci, A., Grilli, S., Mazzullo, M., Prodi, G.,
and Lattanzi, G. Short-term tests of genotoxicity for
1,1,1-trichloroethane. Res. Commun. Chem. Pathol.
Pharmacol. 52: 305-320 (1986).
77. Mazzullo, M., Colacci, A., Grilli, S., Prodi, G., and Arfellini, G.
1,1,2-trichloroethane: evidence of genotoxicity from
short-term tests. Gann 77: 532-539 (1986).
78. Banerjee, S., and Van Duuren, B. L. Covalent binding of the
carcinogen trichloroethylene to hepatic microsomal proteins
and to exogeneous DNA in vitro. Cancer Res. 38: 776-780
(1978).
79. Miller, R. E., and Guengerich, F. P. Metabolism of trichloro-
ethylene in isolated hepatocytes, microsomes, and reconsti-
tuted enzyme systems containing cytochrome P-450. Cancer
Res. 43: 1145-1152 (1983).
80. Sun, L., and Singer, B. The specificity of different classes of
ethylating agents toward various sites of HeLa cell DNA in
vitro and in vivo. Biochemistry 14: 1795-1802 (1975).
81. Swenson, D. H., and Lawley, P. D. Alkylation of deox-
yribonucleic acid by carcinogens dimethyl sulphate, ethyl
methanesulphonate, N-ethyl-N-nitrosourea and N-methyl-N-
nitrosourea. Biochem. J. 171: 575-587 (1978).
82. Morimoto, K., Tanaka, A., and Yamaha, T. Comparative bind-
ing studies on 1,1'-ethylene-bis-(l-nitrosourea) and some 1-
alkyl-l-nitrosoureas with nucleic acids and proteins in vitro.
Gann 70: 693-699 (1979).
83. Bannon, P., and Verly, W. Alkylation ofphosphates and stabil-
ity ofphosphate triesters in DNA. Eur. J. Biochem. 31: 103-111
(1972).
84. Lawley, P. D., and Brookes, P. Further studies on the alkyla-
tion of nucleic acids and their constituent nucleotides.
Biochem. J. 89: 127-138 (1963).
85. Lawley, P. D., Orr, D. J., Shah, S. A., Farmer, P. B., and
Jarman, M. Reaction products from N-methyl-N-nitrosourea
and deoxyribonucleic acid containing thymidine residues.
Biochem. J. 135: 193-201 (1973).
86. Hayatsu, H., and Ukita, T. The modification of nucleosides and
nucleotides. IV. The reaction of semicarbazide with nucleic
acids. Biochim. Biophys. Acta 123: 458-470 (1966).
87. Snedecor, G. W., and Cohran, W. G. Statistical Methods, 6th
Ed. The Iowa State University Press, Ames, IA 1967.
88. Siegel, S. Nonparametric Statistics for the Behavioral Sci-
ences. McGraw-Hill, New York, 1956.